Esperion Stock Downgraded Amid Merck’s Competitive Pressure by Mark Eisenberg 20.06.2024 Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
Otsuka’s Alzheimer Drug AVP-786 Fails Trial Phase by Lilu Anderson 13.02.2024 Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...